About Voltage-gated potassium channel subunit beta-2
Voltage-gated potassium channel subunit beta-2 (KCNAB2) is a protein
from Homo sapiens identified by UniProt accession
Q13303, 367 residues long.
MolForge cross-references it against 0 known binders and
131 disease associations.
Target properties
| Protein name | Voltage-gated potassium channel subunit beta-2 |
|---|
| UniProt accession | Q13303 |
|---|
| Gene | KCNAB2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 367 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (131)
Diseases linked to this target (Open Targets).
- nephronophthisis · score 0.18
- Senior-Loken syndrome · score 0.18
- PHF-tau measurement · score 0.16
- inflammatory bowel disease · score 0.14
- adolescent idiopathic scoliosis · score 0.13
- genetic disorder · score 0.12
- Seizure · score 0.12
- gastric adenocarcinoma · score 0.10
- non-small cell lung carcinoma · score 0.07
- lung adenocarcinoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q13303-F1 | alphafold | PREDICTED | 91.23 | — |
Amino-acid sequence (367 residues)
MYPESTTGSP ARLSLRQTGS PGMIYSTRYG SPKRQLQFYR NLGKSGLRVS CLGLGTWVTF GGQITDEMAE QLMTLAYDNG INLFDTAEVY AAGKAEVVLG NIIKKKGWRR SSLVITTKIF WGGKAETERG LSRKHIIEGL KASLERLQLE YVDVVFANRP DPNTPMEETV RAMTHVINQG MAMYWGTSRW SSMEIMEAYS VARQFNLTPP ICEQAEYHMF QREKVEVQLP ELFHKIGVGA MTWSPLACGI VSGKYDSGIP PYSRASLKGY QWLKDKILSE EGRRQQAKLK ELQAIAERLG CTLPQLAIAW CLRNEGVSSV LLGASNADQL MENIGAIQVL PKLSSSIIHE IDSILGNKPY SKKDYRS
Explore Voltage-gated potassium channel subunit beta-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets